{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:10:50Z","timestamp":1793473850779,"version":"4.5.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ijantimicag.2023.107040","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T18:50:30Z","timestamp":1700506230000},"page":"107040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparing the efficacy and safety of a first-line regimen with emtricitabine\/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5941-883X","authenticated-orcid":false,"given":"Arturo","family":"Ciccullo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmaria","family":"Baldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanni","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Oreni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Lagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3949-4293","authenticated-orcid":false,"given":"Paolo","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Torti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetana","family":"Sterrantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mussini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0569-9407","authenticated-orcid":false,"given":"Spinello","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Di Giambenedetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.107040_bib0001","unstructured":"European AIDS Clinical Society. EACS guidelines. Version 11.0. Brussels: European AIDS Clinical Society; 2021. Available at: https:\/\/www.eacsociety.org\/media\/final2021eacsguidelinesv11.0_oct2021.pdf [accessed 5 June 2022]."},{"key":"10.1016\/j.ijantimicag.2023.107040_bib0002","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Available at: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf [accessed 5 June 2022]."},{"key":"10.1016\/j.ijantimicag.2023.107040_bib0003","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study","volume":"2","author":"Molina","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2023.107040_bib0004","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2023.107040_bib0005","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","article-title":"Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials","volume":"7","author":"Orkin","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2023.107040_bib0006","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1089\/aid.2020.0276","article-title":"Efficacy and safety of dolutegravir plus lamivudine as a first-line regimen in clinical practice","volume":"37","author":"Ciccullo","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.ijantimicag.2023.107040_bib0007","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1080\/14656566.2016.1232387","article-title":"Abacavir\u00a0+\u00a0dolutegravir\u00a0+\u00a0lamivudine for the treatment of HIV","volume":"17","author":"Comi","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ijantimicag.2023.107040_bib0008","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3390\/biomedicines10081823","article-title":"Viro-immunological, clinical outcomes and costs of switching to BIC\/TAF\/FTC in a cohort of people living with HIV: a 48-week prospective analysis","volume":"10","author":"Mazzitelli","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ijantimicag.2023.107040_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-029960","article-title":"Cohort profile: the Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)","volume":"9","author":"Ciccullo","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijantimicag.2023.107040_bib0010","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1001\/jama.286.20.2568","article-title":"Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy","volume":"286","author":"Hogg","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2023.107040_bib0011","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/QAI.0000000000000298","article-title":"Low-level viremia early in HIV infection","volume":"67","author":"Chen","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2023.107040_bib0012","doi-asserted-by":"crossref","first-page":"e26320","DOI":"10.1371\/journal.pone.0026320","article-title":"Association of low level viremia with inflammation and mortality in HIV-infected adults","volume":"6","author":"Eastburn","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2023.107040_bib0013","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/phar.1889","article-title":"Odds of viral suppression by single-tablet regimens, multiple-tablet regimens, and adherence level in HIV\/AIDS patients receiving antiretroviral therapy","volume":"37","author":"Sutton","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2023.107040_bib0014","first-page":"242","article-title":"Single- versus multiple-tablet HIV regimens: adherence and hospitalization risks","volume":"22","author":"Sutton","year":"2016","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.ijantimicag.2023.107040_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147821","article-title":"Cost-effectiveness of single- versus generic multiple-tablet regimens for treatment of HIV-1 infection in the United States","volume":"11","author":"Sweet","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2023.107040_bib0016","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/14787210.2023.2203914","article-title":"Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic review","volume":"21","author":"P\u00e9rez-Valero","year":"2023","journal-title":"Expert Rev Anti Infect Ther"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923003291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923003291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:49:15Z","timestamp":1760377755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923003291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0924857923003291"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.107040","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing the efficacy and safety of a first-line regimen with emtricitabine\/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.107040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107040"}}